Hints and tips:
Related Special Reports
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...After raking in billions of dollars through sales of the Covid vaccine it co-developed with Germany’s BioNTech during the pandemic and seeing share prices surge, Pfizer has struggled to reorientate its pipeline...
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
Case studies in best practice among general counsel and company legal teams in North America
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...overseas co-head is made the scapegoat and fired....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
Carriers have come to rely on check-in charges as a source of revenue but face new disclosure rules
ADM, Chemours, Mattel and NYCB are among groups admitting that weaknesses in controls delayed financial reports
...In a statement, Pfizer said the alleged conduct was a “violation of the company’s policies” and that it was “co-operating with the government’s investigation”....
...Chris Rossbach, a fund manager at J Stern & Co, said it had voted in favour of Disney’s board recommendations....
Warren Buffett-backed company loses some market share to sanctions-hit Chinese telecoms group
...Among the notable patent expiries this decade is BMS and Pfizer’s Eliquis blood clot treatment from 2026. BMS will also lose US exclusivity on its lung cancer treatment Opdivo in 2028....
...The numbers, revealed in consultancy firm Bain & Co’s annual private equity report, show how rapidly the industry has grown over the past decade, as well as the challenges it faces from higher interest rates...
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...Bristol Myers Squibb trades on just seven times earnings while Pfizer is on 20 times. The frenzy for weight loss and diabetes medications is unlikely to fade....
...There have been large investments in vaccine delivery systems in recent years, such as the mRNA technology used for the BioNTech/Pfizer and Moderna Covid-19 vaccines....
“We will lead their coke dealers to their homes after they can’t pay their bills”
Trends in geopolitics force faster responses from legal teams
New survey shows geopolitical turmoil, tough macroeconomic conditions and AI spurring shifts in energy markets
...Once you include the voting proxy arrangement that co-founder and chief executive Steve Huffman has with other investors, he will account for about 46 per cent alone....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
Acquisition might please regulators but would strain jet maker’s liquidity and efficiency measures
International Edition